P/E ratio for Vaxart (VXRT)
P/E ratio as of May 2024 (TTM): -0.9855
According to Vaxart's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.985526. At the end of 2022 the company had a P/E ratio of -1.14.
P/E ratio history for Vaxart from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -1.14 | -89.43% |
| 2021 | -10.8 | -33.74% |
| 2020 | -16.3 | 4654.45% |
| 2019 | -0.3431 | -57.84% |
| 2018 | -0.8139 | -30.04% |
| 2017 | -1.16 | -22.45% |
| 2016 | -1.50 | -33.51% |
| 2015 | -2.26 | -78.85% |
| 2014 | -10.7 | -7.45% |
| 2013 | -11.5 | 180.2% |
| 2012 | -4.11 | -75.93% |
| 2011 | -17.1 | -102.95% |
| 2010 | 579 | -4472.04% |
| 2009 | -13.2 | 42.32% |
| 2008 | -9.31 | -301.06% |
| 2007 | 4.63 | -165.53% |
| 2006 | -7.06 | 349.24% |
| 2005 | -1.57 | -90.88% |
| 2004 | -17.2 | -79.66% |
| 2003 | -84.7 | -141% |
| 2002 | 207 | 5427.13% |
| 2001 | 3.74 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Nymox Pharmaceutical NYMX | -3.33 | 238.23% | Bahamas |
 NRC Health
NRC | 29.4 | -3,081.82% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.